海思科：子公司收到药品补充申请批准通知书

Core Viewpoint - Recently, the company announced that its subsidiary, Shenyang Hisun Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplementary application of the drug,环泊酚注射液 (Ropivacaine Injection) [1] Company Summary - Hisun Pharmaceutical's subsidiary has successfully obtained the approval for Ropivacaine Injection, indicating a positive development in its product portfolio [1]